Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.
Jun 2021 | FROM AKERO THERAPEUTICS
Efruxifermin is Associated With Improved Glucose Metabolism in Patients With NASH and Type 2 Diabetes
Dec 2020 | From Akero Therapeutics
FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases

